Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04266860 · ClinicalTrials.gov registry record · NA
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
A NA study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by Qure Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT04266860 is a NA study of Lupus Nephritis and Lupus Erythematosus, Systemic that has completed, run by Qure Healthcare. The registered enrollment target is 166 participants, below the 305-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04266860, a NA study of Lupus Nephritis and Lupus Erythematosus, Systemic, has completed, sponsored by Qure Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will collect high-quality randomized controlled data from a nationally representative sample of practicing rheumatologists to determine how they currently manage patients with SLE (systemic lupus erythematosus) and how the results of DxTerity's IFN-1 (interferon type I) test change clinical decision making.
Conditions Studied
Interventions
- OTHER Experimental - Test Results and Education
Study Locations (1)
California
- QURE Healthcare - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2012-03-01 |
| Est. Completion | 2013-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04266860
The ClinicalTrials.gov registry entry for NCT04266860 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 305-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (46% lower). The listed sponsor is Qure Healthcare, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Experimental - Test Results and Education is the first listed.
NCT04266860 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04266860 about?
NCT04266860 is a clinical study titled "Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients". This study will collect high-quality randomized controlled data from a nationally representative sample of practicing rheumatologists to determine how they currently manage patients with SLE (systemic lupus erythematosus) and how the results of DxTerity's IFN-1 (interferon type I) test change clinic...
What is the current status of trial NCT04266860?
This trial is currently completed. It is a NA study. The enrollment target is 166 participants. The study started on 2012-03-01. Estimated completion is 2013-03-01.
What conditions does trial NCT04266860 study?
This clinical trial studies the following conditions: Lupus Nephritis, Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT04266860?
The interventions under investigation include: Experimental - Test Results and Education (OTHER).
Who is sponsoring clinical trial NCT04266860?
This trial is sponsored by Qure Healthcare, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04266860 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.